Research Topics
| P WinstanleySummaryAffiliation: University of Liverpool Country: UK Publications
| Collaborators
|
Detail Information
Publications
Beyond registration--measuring the public-health potential of new treatments for malaria in AfricaTrudie Lang
GlaxoSmithKline, Department for Diseases of the Developing World
Lancet Infect Dis 6:46-52. 2006....- Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic rangeP Winstanley
Kenya Medical Research Institute KEMRI, CRC Research Unit, Kilifi, Kenya
Trans R Soc Trop Med Hyg 91:322-7. 1997..These data, together with the clinical trial, will be helpful in deciding whether current chlorproguanil/dapsone doses are optimal for the treatment of falciparum malaria... - Therapy of falciparum malaria in sub-saharan Africa: from molecule to policyPeter Winstanley
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, United Kingdom
Clin Microbiol Rev 17:612-37, table of contents. 2004..The review also discusses the splicing of new drugs into national policy. The various parameters that feed into deliberations on changes in drug policy are discussed... - The contribution of clinical pharmacology to antimalarial drug discovery and developmentPeter Winstanley
Department of Pharmacology and Therapeutics, University of Liverpool, UK
Br J Clin Pharmacol 55:464-8. 2003..Although effective drugs are available, they are largely too expensive for routine use. The present article reviews the ways in which clinical pharmacology has contributed to the identification of new drugs and strategies for malaria... - Coping with malaria in the face of resistancePeter Winstanley
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
Int J Infect Dis 6:246-52. 2002 - Clinical status and implications of antimalarial drug resistancePeter A Winstanley
Department of Pharmacology and Therapeutics, University of Liverpool, L69 3GE, Liverpool, UK
Microbes Infect 4:157-64. 2002..Artemisinin combination therapy may offer considerable advantages over alternative therapies, but its introduction faces considerable logistic difficulty... - Modern chemotherapeutic options for malariaP Winstanley
Department of Pharmacology and Therapeutics, and Wellcome Trust Centre for Research in Clinical Tropical Medicine, University of Liverpool, UK
Lancet Infect Dis 1:242-50. 2001..The article then examines the challenges faced in the processes of changing policy, and the implementation of that policy shift... - Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malariaP Winstanley
Department of Pharmacology and Therapeutics, University of Liverpool, UK
Trop Med Int Health 6:952-4. 2001..This short paper outlines the current stages that LAPDAP and CDA have reached, and sketches the anticipated public health issues... - Chemotherapy for falciparum malaria: the armoury, the problems and the prospectsP A Winstanley
Department of Pharmacology and Therapeutics, The University of Liverpool, UK L69 3GE
Parasitol Today 16:146-53. 2000..He then examines some of the current major problems and prospects for the future... - Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsoneJulie A Simpson
Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia
Br J Clin Pharmacol 61:289-300. 2006.... - Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?Alexis Nzila
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P O Box 43640, 00100 GPO, Nairobi, Kenya
Trans R Soc Trop Med Hyg 99:341-6. 2005..In this paper, we discuss briefly the reasons why Leu-164 has not yet been selected in Africa and we propose a means that may slow down the selection of this mutation... - Malaria chemotherapyPeter Winstanley
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, UK
Adv Parasitol 61:47-76. 2006..We give no apology for placing our emphasis upon the use of antimalarial drugs in endemic populations rather than their use for prophylaxis in travellers... - Current issues in the treatment of uncomplicated malaria in AfricaDavid Bell
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, UK
Br Med Bull 71:29-43. 2004..This article reviews the rationale behind combination therapy, the drugs available and the available evidence from combination therapy trials in Africa. Treatment of uncomplicated malaria in pregnancy and infants is also discussed... - Chemosensitization of Plasmodium falciparum by probenecid in vitroAlexis Nzila
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, Nairobi, Kenya
Antimicrob Agents Chemother 47:2108-12. 2003..P. Thompson & Co., Liverpool, United Kingdom] has been filed to protect this intellectual property)... - The potential for interactions between antimalarial and antiretroviral drugsSaye Khoo
AIDS 19:995-1005. 2005 - Developmental toxicity of artesunate and an artesunate combination in the rat and rabbitRobert L Clark
Safety Assessment, GlaxoSmithKline, King of Prussia, Pa 19406 0939, USA
Birth Defects Res B Dev Reprod Toxicol 71:380-94. 2004..Investigations of the mechanism of developmental toxicity are ongoing to attempt to determine whether rats and rabbits are more sensitive to artemisinins than humans...